Hepatic Arterial Chemotherapy for Metastatic Colorectal Carcinoma
Author Information
Author(s): P.G. de Takats, D.J. Kerr, C.J. Poole, H.W. Warren, C.S. McArdle
Hypothesis
Can regional chemotherapy improve response rates and survival in patients with hepatic metastases from colorectal carcinoma?
Conclusion
While hepatic arterial infusion chemotherapy can achieve higher response rates, it does not significantly improve patient survival compared to conventional intravenous administration.
Supporting Evidence
- Higher response rates (42-62%) were achieved with regional therapy compared to systemic therapy (10-21%).
- Patients with isolated liver metastases had a median survival of 3-5 months.
- Complications from catheter placement included nausea, vomiting, and sepsis.
Takeaway
Doctors are trying to give medicine directly to the liver to help people with cancer, but it doesn't always make them live longer.
Methodology
The study reviewed pharmacokinetic principles and clinical experiences with hepatic arterial drug administration.
Potential Biases
The studies included were mostly non-randomized and had varying methodologies, which may introduce bias.
Limitations
The studies reviewed showed no significant survival benefit despite higher response rates, and many patients still experienced complications.
Participant Demographics
Patients with metastatic colorectal carcinoma, particularly those with liver metastases.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website